LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Inverness Medical to Acquire Binax

By Labmedica staff writers
Posted on 17 Feb 2005
In a move to expand the company's technology base, Inverness Medical Innovations, Inc. (Waltham, MA, USA) has agreed to acquire Binax, Inc. (Portland, ME, USA).

Under the terms of the agreement, Inverness will acquire all of the stock of Binax in exchange for 1.4 million shares of its common stock and additional consideration of U.S.$8.6 million in cash at closing. The agreement also provides for additional consideration to Binax shareholders of up to $11 million in cash contingent upon Binax meeting certain new-product development objectives over five years.

Inverness is a leading global supplier of advanced diagnostic devices and is exploring new opportunities for its proprietary electrochemical and other technologies in a variety of applications, including immuno-diagnostics with a focus on women's health, cardiology, and infectious disease. "We expect to benefit from Binax's established reputation in respiratory diagnostics, and we are excited about the potential new-product development opportunities,” said Ron Zwanziger, CEO of Inverness Medical.

Binax is developing rapid diagnostic kits for the identification of pathogens causing infectious diseases. "By leveraging our combined resources and expertise, we expect to be able to improve our ability to deliver significant and innovative new products to point-of-care diagnostic markets,” remarked Roger Piasio, CEO of Binax.





Related Links:
Inverness
Binax
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more